Haemonetics to Present at 44th Annual J.P. Morgan Healthcare Conference

Haemonetics Corporation, a leading global medical technology company, is set to present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco. The presentation will take place on January 13, 2026, at 7:30 AM Pacific Time, featuring insights from Chris Simon, the company’s President and CEO. This conference is one of the premier events in the healthcare sector, bringing together investors, executives, and healthcare professionals to discuss industry trends and innovations.

Investors and interested parties can access a live audio webcast of the presentation through a provided link, with a replay available for 30 days following the event. This allows stakeholders to gain valuable information regarding Haemonetics’ strategic direction and future initiatives after the live presentation has concluded. The webcast will be hosted on Haemonetics' Investor Relations website, underscoring the company's commitment to transparency and shareholder engagement.

Haemonetics is focused on advancing healthcare quality and efficiency through innovative medical solutions. The company’s product offerings include technologies designed to enhance hospital care standards, optimize operations for plasma collection centers, and improve the gathering of essential blood components for transfusions. By addressing these critical medical needs, Haemonetics aims to improve patient outcomes across the healthcare spectrum.

For further information or inquiries regarding the event, investors and the media can contact the designated representatives from the company, including Olga Guyette for Investor Relations and Josh Gitelson for communications. The forthcoming presentation at the J.P. Morgan Healthcare Conference is anticipated to shed light on Haemonetics' future growth and its role in shaping healthcare technology solutions. For more detailed information, stakeholders can visit Haemonetics' official website.

Haemonetics Corporation's participation in the 44th Annual J.P. Morgan Healthcare Conference presents a significant opportunity for investors to assess the company's strategic direction and market prospects. As a key player in the medical technology space, Haemonetics specializes in solutions that address critical medical needs—including advanced hospital technologies and plasma collection systems.

In the lead-up to the conference, investors should closely monitor several key themes that may arise during Chris Simon's presentation. First, the ongoing advancements in healthcare technologies and products designed to improve patient outcomes are essential. Haemonetics' focus on innovation suggests that they may unveil new initiatives or product lines aimed at increasing operational efficiencies in blood and plasma collection, which are expected to be growth catalysts.

Moreover, the overall outlook for the healthcare sector remains robust, buoyed by increased healthcare spending and a growing demand for healthcare technologies. Investors should evaluate how Haemonetics plans to capitalize on these trends, particularly through any partnerships or collaborations that could enhance their market position.

Financial performance metrics and guidance could also be a focal point during the presentation. Investors should watch for updates on revenue growth, profit margins, and any strategic shifts that may impact future performance. Given Haemonetics’ commitment to improving quality and efficiency in healthcare, insights into their competitive advantages—such as proprietary technologies or market share—will be critical in making investment decisions.

In summary, attending the J.P. Morgan Healthcare Conference will provide valuable insights into Haemonetics’ strategic plans and market positioning. Investors should remain attentive to the evolving landscape of medical technology and consider how Haemonetics aligns with broader industry trends as they formulate their investment strategies.